Previous 10 | Next 10 |
home / stock / mrna / mrna articles
On Friday, Pfizer Inc (NYSE: PFE) revealed its drug for an advanced form of lung cancer showed promising long-term results in a late-stage tri...
Moderna (NASDAQ:MRNA) has outperformed the market over the past 5 years by 40.36% on an annualized basis producing an average annual return of 53.1...
Monday, Moderna Inc (NASDAQ:MRNA) and Merck & Co Inc (NYSE:MRK) announced the first presentation of results from a planned analysis f...
On Wednesday, Ark Invest, led by the influential investor Cathie Wood, executed notable trades involving Robinhood Markets Inc (NASDAQ:HOOD), Moder...
On Wednesday, Ark Invest, led by the influential investor Cathie Wood, executed notable trades involving Robinhood Markets Inc (NASDAQ:HOOD), Moder...
On Tuesday, Cathie Wood-led Ark Invest made significant trades involving Advanced Micro Devices Inc (NASDAQ:AMD), Palantir Technologies Inc (NYSE:P...
On CNBC's “Mad Money Lightning Round,” Jim Cramer called Celestica Inc. (NYSE:CLS) “terrific” after the Toronto-based ...
These large-cap stocks were the best performers in the last week. Are they in your portfolio? First Solar, Inc. (NASDAQ:FSLR) shares jumped 41.5%...
Shares of vaccine producers' stocks are trading higher Wednesday on reports indicating disease experts predict a small rise in COVID-19 cases ...
News, Short Squeeze, Breakout and More Instantly...
CAMBRIDGE, MA / ACCESSWIRE / July 10, 2024 / Moderna, Inc. (NASDAQ:MRNA), today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Thursday, August 1, 2024 to report its second quarter 2024 financial results, and provide a corporate update. A live webcast of the c...
CAMBRIDGE, MA AND OSAKA, JAPAN / ACCESSWIRE / July 8, 2024 / Moderna, Inc. (Nasdaq:MRNA) and Mitsubishi Tanabe Pharma Corporation today announced that the companies have entered into a joint agreement regarding the co-promotion of Moderna's mRNA respiratory vaccine portfolio in Japan, including ...
CAMBRIDGE, MA / ACCESSWIRE / July 2, 2024 / Moderna, Inc. (NASDAQ:MRNA) today announced a project award of $176 million through the Rapid Response Partnership Vehicle (RRPV) to accelerate the development of mRNA-based pandemic influenza vaccines. The RRPV is a Consortium funded by the Biomedical...